Quick Answer
Cue Biopharma, Inc. reported Total Revenue of $27.47 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +195.7% in Total Revenue from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $172.0 thousand | Q3 2018: $449.0 thousand | Q1 2019: $370.0 thousand | Q2 2019: $1.06 million | Q3 2019: $984.0 thousand | Q1 2020: $900.0 thousand | Q2 2020: $1.08 million | Q3 2020: $704.0 thousand | Q1 2021: $1.55 million | Q2 2021: $2.74 million | Q3 2021: $2.40 million | Q1 2022: $1.00 million | Q2 2022: $26.0 thousand | Q3 2022: $68.0 thousand | Q1 2023: $187.0 thousand | Q2 2023: $1.38 million | Q3 2023: $2.10 million | Q1 2024: $1.72 million | Q2 2024: $2.66 million | Q3 2024: $3.34 million | Q1 2025: $421.0 thousand | Q2 2025: $2.95 million | Q3 2025: $2.15 million.
- Over the full 8 years of available data (2018 to 2025), Cue Biopharma, Inc.'s Total Revenue has grown by 2,303.8%.
- Historical annual values: Fiscal year 2025: $27.47 million | Fiscal year 2024: $9.29 million | Fiscal year 2023: $5.49 million | Fiscal year 2022: $1.25 million | Fiscal year 2021: $14.94 million | Fiscal year 2020: $3.15 million | Fiscal year 2019: $3.46 million | Fiscal year 2018: $1.14 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: